Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

European Medicines Agency fast-tracks new multiple myeloma drug

The European Medicines Agency (EMA) has fast-tracked the approval of the drug elotuzumab (Empliciti) for the treatment of multiple myeloma.

The European Medicines Agency (EMA) has fast-tracked the approval of the drug elotuzumab (Empliciti) for the treatment of multiple myeloma. The drug helps to activate the body’s immune system to fight against the cancer, and is to be used in combination with lenalidomide and the anti-inflammatory medicine dexamethasone for the treatment of patients who have received at least one prior therapy. Elotuzumab is a monoclonal antibody that works by activating the body’s immune system to attack and kill multiple myeloma cells. Multiple myeloma is a rare malignant disease of a type of white blood cells called plasma cells. In multiple

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy